Salutaris Medical Devices, Inc. (SMD)
- Home
- Companies
- Salutaris Medical Devices, Inc. (SMD)
- Services
- Current Treatment for Wet-AMD
Current Treatment for Wet-AMD
Anti-VEGF Resistant Disease; 20+ million seniors suffer vision loss from wet-AMD (advanced age-related macular degeneration). The current treatment for wet-AMD is frequent (sometimes monthly) injections of anti-VEGF directly into the eye.
Most popular related searches
This treatment is a $15+ billion industry but these lifetime injections produce disappointing results in up to 60% of wet-AMD patients.
Many of these non-responsive patients often suffer from a subtype, PCV (polypoidal choroidal vasculopathy), that remains under-diagnosed outside of Asia due to its disproportionate impact on darkly pigmented individuals. PCV has proven to be a difficult puzzle to solve.